(Q47988504)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23864305%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

title

Rapid blood clearance and lack of long-term renal toxicity of 177Lu-DOTATATE enables shortening of renoprotective amino acid infusion (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23864305%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23864305%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Rodney J. Hicks

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23864305%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Jean-Mathieu Beauregard

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23864305%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

Price Jackson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23864305%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Michael S Hofman

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23864305%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Peter Eu

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23864305%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Diana Zannino

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23864305%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

publication date

18 July 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23864305%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Nuclear Medicine and Molecular Imaging

5 March 2020

number of pages

8

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23864305%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

volume

40

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23864305%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23864305%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

page(s)

1853-1860

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23864305%20AND%20SRC:MED&resulttype=core&format=json

Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study

5 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2504-X

Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2504-X

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2504-X

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2504-X

Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2504-X

177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2504-X

Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2504-X

Renal toxicity after radionuclide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2504-X

Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2504-X

Localisation and mechanism of renal retention of radiolabelled somatostatin analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2504-X

Cerebral deafferentiation in operated gliomas as a predictor for malignancy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2504-X

Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2504-X

End-stage renal disease after treatment with 90Y-DOTATOC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2504-X

Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2504-X

Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2504-X

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2504-X

86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2504-X

Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2504-X

Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2504-X

Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2504-X

Quantitative (177)Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2504-X

Monitoring renal function during chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2504-X

Longitudinal studies on the rate of decline in renal function with age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2504-X

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2504-X

The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2504-X

Effect of amino acid infusion on potassium serum levels in neuroendocrine tumour patients treated with targeted radiopeptide therapy

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23864305

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Yttrium-90 DOTATOC: first clinical results

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23864305